Cargando…

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study

BACKGROUND: The cost-effectiveness of immunisation strategies with a long-acting monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for protecting infants from Respiratory Syncytial Virus (RSV)-associated illness has not been previously determined for Canada. We estim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoukat, Affan, Abdollahi, Elaheh, Galvani, Alison P., Halperin, Scott A., Langley, Joanne M., Moghadas, Seyed M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663690/ https://www.ncbi.nlm.nih.gov/pubmed/38026446 http://dx.doi.org/10.1016/j.lana.2023.100629

Ejemplares similares

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults
por: Baber, James A, et al.
Publicado: (2023)

Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada
por: Nourbakhsh, Shokoofeh, et al.
Publicado: (2021)

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers
por: Zhang, Kevin, et al.
Publicado: (2021)

Routine saliva testing for the identification of silent COVID-19 infections in healthcare workers
por: Zhang, Kevin, et al.
Publicado: (2020)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated
por: Schwarz, Tino, et al.
Publicado: (2020)

2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
por: Chandler, Reynaldo, et al.
Publicado: (2022)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
por: Guiñazú, Javier Ruiz, et al.
Publicado: (2020)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

Simulating the effect of school closure during COVID-19 outbreaks in Ontario, Canada
por: Abdollahi, Elaheh, et al.
Publicado: (2020)

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
por: Tica, Jelena, et al.
Publicado: (2020)

Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination
por: Moghadas, Seyed M., et al.
Publicado: (2021)

Simulated identification of silent COVID-19 infections among children and estimated future infection rates with vaccination
por: Moghadas, Seyed M., et al.
Publicado: (2021)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

The implications of silent transmission for the control of COVID-19 outbreaks
por: Moghadas, Seyed M., et al.
Publicado: (2020)

Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic
por: Vilches, Thomas N., et al.
Publicado: (2022)

Importance of non-pharmaceutical interventions in the COVID-19 vaccination era: A case study of the Seychelles
por: Vilches, Thomas N, et al.
Publicado: (2021)

Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia
por: Shoukat, Affan, et al.
Publicado: (2018)

Dynamics of HSV-2 infection with a therapeutic vaccine
por: Venturino, Ezio, et al.
Publicado: (2020)

Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
por: Shoukat, Affan, et al.
Publicado: (2019)

Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study
por: Vilches, Thomas N., et al.
Publicado: (2022)

The impact of vaccination on COVID-19 outbreaks in the United States
por: Moghadas, Seyed M., et al.
Publicado: (2021)

The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
por: Moghadas, Seyed M, et al.
Publicado: (2021)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

Quantifying the potential dominance of immune-evading SARS-CoV-2 variants in the United States
por: Sah, Pratha, et al.
Publicado: (2021)

Potential resurgence of respiratory syncytial virus in Canada
por: Lavoie, Pascal M., et al.
Publicado: (2021)

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Jones, Jefferson M., et al.
Publicado: (2023)

Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada
por: Vilches, Thomas N., et al.
Publicado: (2021)

Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada
por: Vilches, Thomas N., et al.
Publicado: (2021)

Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas
por: Sah, Pratha, et al.
Publicado: (2021)

COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA
por: Vilches, Thomas N., et al.
Publicado: (2021)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study
por: Shoukat, Affan, et al.
Publicado: (2021)

Possible résurgence du virus respiratoire syncytial au Canada
por: Lavoie, Pascal M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qtfasicol4ljlcd1q7p97lga85